Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial
Top Cited Papers
- 15 September 2002
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (18) , 3815-3825
- https://doi.org/10.1200/jco.2002.03.038
Abstract
PURPOSE: To investigate safety, tolerability, dose-related pharmacologic properties, and pharmacodynamics of ZD1839 (gefinitib, Iressa; AstraZeneca Pharmacueticals, Wilmington, DE), an epidermal gr...Keywords
This publication has 29 references indexed in Scilit:
- Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)Lung Cancer, 2000
- Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cellsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2000
- Epidermal growth factor-related peptides and their receptors in human malignanciesPublished by Elsevier ,2000
- EGF receptorThe International Journal of Biochemistry & Cell Biology, 1999
- The Epidermal Growth Factor Receptor and Its Inhibition in Cancer TherapyPharmacology & Therapeutics, 1999
- Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomasBritish Journal of Cancer, 1998
- Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trialsAnnals of Oncology, 1997
- Antiapoptotic Signalling by the Insulin-Like Growth Factor I Receptor, Phosphatidylinositol 3-Kinase, and AktMolecular and Cellular Biology, 1997
- The Epidermal Growth Factor Receptor in Breast CancerJournal of Mammary Gland Biology and Neoplasia, 1997
- Growth Factors and CancerScience, 1991